3Yuen MF, Seto WK, Chow therapy reduces the risk of hepatitis B infection even in DH, et al. Long-term lamivudine long-term complications of chronic patients without advanced disease.Antivir Ther, 2007,12(8):1295.
4Kim DY, Ahn SH, Lee HW, et al. Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. Intervirology, 2008,51(4):293.
5Kurashige N, Hiramatsu N, Ohkawa K. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. Hepatol Res, 2008,38(5):450.
6Yen YH, Lu SN, Chen CH, et al.Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int, 2007,27(10):1349.
4Torbenson M, Thomas DL, Occult hepatitis B. Lancet Infect Dis, 2002,2 : 479-486.
5Kao JH, Chen PJ, Lai MY, et al. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol, 2002,40 : 4068-4071.
6Jeantet D, Chemin I, Mandrand B, et al. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology,2002,35 : 1215-1224.
7Aoki M, Saito T, Watanabe H, et al. Clinical significance of a highly sensitive enzyme immunoassay of hepatitis B surface antigen using a novel electron spin resonance technique. J Med Virol,2002,66 : 166-170.
8Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat, 2002,9:243-257.
9Kao JH, Chen PJ, Lai MY, et al. Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. J Med Virol, 2002,68 : 216-220.
10Zanella I, Rossini A, Domenighini D, et al. Quantitive analysis of hepatitis B virus DNA by real-lime amplification. Eur J Clin Microbiol Infect Dis, 2002,21 : 22-26.
6Natsuizaka M, Hige S, Ono Y, et al. Longterm follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus PoIymerase region[J].J Viral Hepat,2005, 12:154-159.
7Terrauh NA. Benefits and risks of combination therapy for hepatitis B [ J ]. Hepatology, 2009, 49(5 Suppl) :S122 - 128.
9Natsuizaka M, Hige S, Ono Y, et al. Long - term follow - up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus Polymerase region [ J ]. J Vira Hepat, 2005, 12 : 154 - 159.
10Schalm SW, Heathcote J, Cianciara J, et al.Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection : a randomised trial [ J ]. Gut, 2000, 46:562 - 568.
